title: Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
abstract: To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140 mg starting dose (50.0% vs 19.6%, p=0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140 mg (88.4% vs 26.7%, p<0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100mg/day, is effective and safe also in unselected elderly subjects.
authors.affiliation: Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Rome, Italy. rob.lati@libero.it
authors.forename: Roberto
authors.initials: R
authors.lastname: Latagliata
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Fausto
authors.initials: F
authors.lastname: Castagnetti
authors.forename: Fabio
authors.initials: F
authors.lastname: Stagno
authors.forename: Luigiana
authors.initials: L
authors.lastname: Luciano
authors.forename: Antonella
authors.initials: A
authors.lastname: Gozzini
authors.forename: Stefano
authors.initials: S
authors.lastname: Ulisciani
authors.forename: Francesco
authors.initials: F
authors.lastname: Cavazzini
authors.forename: Mario
authors.initials: M
authors.lastname: Annunziata
authors.forename: Federica
authors.initials: F
authors.lastname: Sorà
authors.forename: Antonella Russo
authors.initials: AR
authors.lastname: Rossi
authors.forename: Patrizia
authors.initials: P
authors.lastname: Pregno
authors.forename: Enrico
authors.initials: E
authors.lastname: Montefusco
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Abruzzese
authors.forename: Elena
authors.initials: E
authors.lastname: Crisà
authors.forename: Pellegrino
authors.initials: P
authors.lastname: Musto
authors.forename: Mario
authors.initials: M
authors.lastname: Tiribelli
authors.forename: Gianni
authors.initials: G
authors.lastname: Binotto
authors.forename: Ubaldo
authors.initials: U
authors.lastname: Occhini
authors.forename: Costanzo
authors.initials: C
authors.lastname: Feo
authors.forename: Paolo
authors.initials: P
authors.lastname: Vigneri
authors.forename: Valeria
authors.initials: V
authors.lastname: Santini
authors.forename: Carmen
authors.initials: C
authors.lastname: Fava
authors.forename: Giannantonio
authors.initials: G
authors.lastname: Rosti
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D012189:Retrospective Studies; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib